BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24823463)

  • 1. Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma.
    Mendola M; Passeri E; Ambrosi B; Corbetta S
    J Clin Endocrinol Metab; 2014 Aug; 99(8):2623-4. PubMed ID: 24823463
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-lasting complete remission after therapy with temozolomide in two patients with macrocorticotropinoma causing Cushing's disease.
    Bruno OD; Juárez-Allen L; Christiansen SB; Danilowicz K
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):143-5. PubMed ID: 25611185
    [No Abstract]   [Full Text] [Related]  

  • 3. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
    Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
    Campderá M; Palacios N; Aller J; Magallón R; Martín P; Saucedo G; Lilienfeld H; Estrada J
    Pituitary; 2016 Apr; 19(2):158-66. PubMed ID: 26586560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
    Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
    Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
    Gilis-Januszewska A; Wilusz M; Pantofliński J; Turek-Jabrocka R; Sokołowski G; Sowa-Staszczak A; Kluczyński Ł; Pach D; Zieliński G; Hubalewska-Dydejczyk A
    Endokrynol Pol; 2018; 69(3):306-312. PubMed ID: 29319131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.
    Salehi F; Scheithauer BW; Moyes VJ; Drake WM; Syro LV; Manoranjan B; Sharma S; Horvath E; Kovacs K
    Endocr Pathol; 2010 Dec; 21(4):227-9. PubMed ID: 21061089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
    Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
    Thearle MS; Freda PU; Bruce JN; Isaacson SR; Lee Y; Fine RL
    Pituitary; 2011 Dec; 14(4):418-24. PubMed ID: 19960369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
    Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
    Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment.
    Kurowska M; Tarach JS; Malicka J; Zieliński G; Maksymowicz M; Denew P
    Endokrynol Pol; 2016; 67(5):526-533. PubMed ID: 27828691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of brain metastases of malignant melanoma with temozolomide.
    Biasco G; Pantaleo MA; Casadei S
    N Engl J Med; 2001 Aug; 345(8):621-2. PubMed ID: 11529230
    [No Abstract]   [Full Text] [Related]  

  • 13. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.
    Dillard TH; Gultekin SH; Delashaw JB; Yedinak CG; Neuwelt EA; Fleseriu M
    Pituitary; 2011 Mar; 14(1):80-91. PubMed ID: 20972839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
    Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
    Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide as prophylaxis for melanoma brain metastases.
    Conill C; González-Cao M; Jorcano S; Puig S; Malvehy J; Martí R; Castel T
    Melanoma Res; 2004 Feb; 14(1):73-4. PubMed ID: 15091198
    [No Abstract]   [Full Text] [Related]  

  • 16. Temozolomide and pituitary adenoma.
    Hueng DY; Ma HI; Sytwu HK; Liu MY
    J Neurosurg; 2011 Jun; 114(6):1820: author reply 1820-1. PubMed ID: 21513431
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical, Laboratory, and Treatment Profiles of Silent Corticotroph Adenomas That Have Transformed to the Functional Type: A Case Series With a Literature Review.
    Zheng G; Lu L; Zhu H; You H; Feng M; Liu X; Dai C; Yao Y; Wang R; Zhang H; Sun X; Lu Z
    Front Endocrinol (Lausanne); 2020; 11():558593. PubMed ID: 33071973
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of temozolomide in aggressive pituitary tumors: case report.
    Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
    Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
    Zacharia BE; Gulati AP; Bruce JN; Carminucci AS; Wardlaw SL; Siegelin M; Remotti H; Lignelli A; Fine RL
    Neurosurgery; 2014 Apr; 74(4):E447-55; discussion E455. PubMed ID: 24226425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy.
    Zauderer M; Krug LM; Pietanza MC; O'Rourke D
    J Thorac Oncol; 2010 Oct; 5(10):1716-7. PubMed ID: 20871272
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.